These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 16271760)

  • 1. Inverse correlation between Flt3 and PU.1 expression in acute myeloblastic leukemias.
    Inomata M; Takahashi S; Harigae H; Kameoka J; Kaku M; Sasaki T
    Leuk Res; 2006 Jun; 30(6):659-64. PubMed ID: 16271760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Over-expression of Flt3 induces NF-kappaB pathway and increases the expression of IL-6.
    Takahashi S; Harigae H; Ishii KK; Inomata M; Fujiwara T; Yokoyama H; Ishizawa K; Kameoka J; Licht JD; Sasaki T; Kaku M
    Leuk Res; 2005 Aug; 29(8):893-9. PubMed ID: 15978940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Upregulation of c-myc gene accompanied by PU.1 deficiency in radiation-induced acute myeloid leukemia in mice.
    Hirouchi T; Takabatake T; Yoshida K; Nitta Y; Nakamura M; Tanaka S; Ichinohe K; Oghiso Y; Tanaka K
    Exp Hematol; 2008 Jul; 36(7):871-85. PubMed ID: 18375040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FLT3-ITD induces ara-C resistance in myeloid leukemic cells through the repression of the ENT1 expression.
    Jin G; Matsushita H; Asai S; Tsukamoto H; Ono R; Nosaka T; Yahata T; Takahashi S; Miyachi H
    Biochem Biophys Res Commun; 2009 Dec; 390(3):1001-6. PubMed ID: 19853583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Purine-rich box-1-mediated reduced expression of CD20 alters rituximab-induced lysis of chronic lymphocytic leukemia B cells.
    Mankaï A; Bordron A; Renaudineau Y; Martins-Carvalho C; Takahashi S; Ghedira I; Berthou C; Youinou P
    Cancer Res; 2008 Sep; 68(18):7512-9. PubMed ID: 18794139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Constitutive activation of Flt3 and STAT5A enhances self-renewal and alters differentiation of hematopoietic stem cells.
    Moore MA; Dorn DC; Schuringa JJ; Chung KY; Morrone G
    Exp Hematol; 2007 Apr; 35(4 Suppl 1):105-16. PubMed ID: 17379095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detailed analysis of FLT3 expression levels in acute myeloid leukemia.
    Kuchenbauer F; Kern W; Schoch C; Kohlmann A; Hiddemann W; Haferlach T; Schnittger S
    Haematologica; 2005 Dec; 90(12):1617-25. PubMed ID: 16330434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PU.1 and CEBPA expression in acute myeloid leukemia.
    D'Alò F; Di Ruscio A; Guidi F; Fabiani E; Greco M; Rumi C; Hohaus S; Voso MT; Leone G
    Leuk Res; 2008 Sep; 32(9):1448-53. PubMed ID: 18308386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NF-κB/STAT5/miR-155 network targets PU.1 in FLT3-ITD-driven acute myeloid leukemia.
    Gerloff D; Grundler R; Wurm AA; Bräuer-Hartmann D; Katzerke C; Hartmann JU; Madan V; Müller-Tidow C; Duyster J; Tenen DG; Niederwieser D; Behre G
    Leukemia; 2015 Mar; 29(3):535-47. PubMed ID: 25092144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PU.1 downregulation in murine radiation-induced acute myeloid leukaemia (AML): from molecular mechanism to human AML.
    Verbiest T; Bouffler S; Nutt SL; Badie C
    Carcinogenesis; 2015 Apr; 36(4):413-9. PubMed ID: 25750172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aberrant expression of CD7 in myeloblasts is highly associated with de novo acute myeloid leukemias with FLT3/ITD mutation.
    Rausei-Mills V; Chang KL; Gaal KK; Weiss LM; Huang Q
    Am J Clin Pathol; 2008 Apr; 129(4):624-9. PubMed ID: 18343790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FLT3 mutations in a 10 year consecutive series of 177 childhood acute leukemias and their impact on global gene expression patterns.
    Andersson A; Paulsson K; Lilljebjörn H; Lassen C; Strömbeck B; Heldrup J; Behrendtz M; Johansson B; Fioretos T
    Genes Chromosomes Cancer; 2008 Jan; 47(1):64-70. PubMed ID: 17943971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aggressive acute myeloid leukemia in PU.1/p53 double-mutant mice.
    Basova P; Pospisil V; Savvulidi F; Burda P; Vargova K; Stanek L; Dluhosova M; Kuzmova E; Jonasova A; Steidl U; Laslo P; Stopka T
    Oncogene; 2014 Sep; 33(39):4735-45. PubMed ID: 24121269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of annexin 1 as a PU.1 target gene in leukemia cells.
    Iseki Y; Imoto A; Okazaki T; Harigae H; Takahashi S
    Leuk Res; 2009 Dec; 33(12):1658-63. PubMed ID: 19428102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Soluble phosphorylated fms-like tyrosine kinase III. FLT3 protein in patients with acute myeloid leukemia (AML).
    Ravandi F; Jilani I; Estey E; Kantarjian H; Dey A; Aguilar C; Jitkaroon C; Giles F; O'Brien S; Keating M; Albitar M
    Leuk Res; 2007 Jun; 31(6):791-7. PubMed ID: 17156841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MS-275, a novel histone deacetylase inhibitor with selectivity against HDAC1, induces degradation of FLT3 via inhibition of chaperone function of heat shock protein 90 in AML cells.
    Nishioka C; Ikezoe T; Yang J; Takeuchi S; Koeffler HP; Yokoyama A
    Leuk Res; 2008 Sep; 32(9):1382-92. PubMed ID: 18394702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PU.1 can regulate the ZNF300 promoter in APL-derived promyelocytes HL-60.
    Xu JH; Wang T; Wang XG; Wu XP; Zhao ZZ; Zhu CG; Qiu HL; Xue L; Shao HJ; Guo MX; Li WX
    Leuk Res; 2010 Dec; 34(12):1636-46. PubMed ID: 20471086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multistep pathogenesis of leukemia via the MLL-AF4 chimeric gene/Flt3 gene tyrosine kinase domain (TKD) mutation-related enhancement of S100A6 expression.
    Yamaguchi H; Hanawa H; Uchida N; Inamai M; Sawaguchi K; Mitamura Y; Shimada T; Dan K; Inokuchi K
    Exp Hematol; 2009 Jun; 37(6):701-14. PubMed ID: 19463771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heterozygous deletion of the PU.1 locus in human AML.
    Bonadies N; Pabst T; Mueller BU
    Blood; 2010 Jan; 115(2):331-4. PubMed ID: 19890096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FLT3 inhibitor KRN383 on xenografted human leukemic cells harboring FLT3-activating mutations FLT3 in AML: much more to learn about biology and optimal targeting.
    Giles FJ
    Leuk Res; 2006 Dec; 30(12):1469-70. PubMed ID: 16631251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.